Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325870 | 0.82 | PTGS2 (0.54) | KDM4EL3MBTL1PDE4BATMMEN1 | |
| Ammonia Solution, Strong SCHEMBL303558 | 0.81 | PTGS2 (0.52) | KDM4EL3MBTL1PDE4BATMMEN1 | |
| Leucine SCHEMBL18074075 | 0.79 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| Leucine SCHEMBL18074074 | 0.79 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28323447 | 0.79 | LDHA (0.60) | KDM4EL3MBTL1MEN1KMT2ALDHA | |
| D-Leucine SCHEMBL15300397 | 0.77 | LMNA (0.46) | PDE4BMEN1KMT2APOLBPDE4A | |
| Leucine SCHEMBL28042299 | 0.77 | LMNA (0.46) | PDE4BMEN1KMT2APOLBPDE4A | |
| Leucine SCHEMBL15194106 | 0.77 | LMNA (0.46) | PDE4BMEN1KMT2APOLBPDE4A | |
| SCHEMBL11446231 | 0.72 | SLC7A5 (0.54) | KDM4EMEN1KMT2ALDHAPTGS2 | |
| SCHEMBL4456615 | 0.71 | L3MBTL1 (0.47) | KDM4EL3MBTL1PDE4BKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | claimed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | claimed |
| EP-3524242-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | Celgene Corporation (US) | 2019-08-14 | — | — | EP | claimed |
| EP-2420490-B1 | Method for the preparation of (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORP (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2420490-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | claimed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| EP-4168390-A1 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | BIOHORM, S.L. (ES) | 2023-04-26 | — | — | EP | disclosed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2021259860-A1 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | BIOHORM, S.L. (ES) | 2021-12-30 | — | — | WO | disclosed |
| US-11040024-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | AMGEN INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3320902-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | AMGEN EUROPE GMBH (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | disclosed |
| US-20060183788-A1 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION | 2006-08-17 | — | — | US | disclosed |
| US-20050267196-A1 | Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| US-6962940-B2 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | CELGENE CORPORATION (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | LARS1 2448/4885KDM4E 1755/4885L3MBTL1 2785/4885 |
| US-11040024-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | PDE4A, PDE2A, PDE4B | LARS1 3568/4885KDM4E 1263/4885L3MBTL1 4173/4885 |
| US-20060183788-A1 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CHRM3, CHRM1, CHRM2 | LARS1 4402/4885KDM4E 1936/4885L3MBTL1 4189/4885 |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | IL4, PTGER4, PDE4A | LARS1 4168/4885KDM4E 1668/4885L3MBTL1 4524/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | LARS1 3513/4885KDM4E 891/4885L3MBTL1 4232/4885 |
| US-20050267196-A1 | Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants | PDE4A, TNF, PDE4B | LARS1 2347/4885KDM4E 944/4885L3MBTL1 4422/4885 |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | PDE4A, PDE4B, PDE2A | LARS1 3513/4885KDM4E 891/4885L3MBTL1 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.